Information  X 
Enter a valid email address

Tissue Regenix Group (TRX)

  Print   

Tuesday 05 January, 2021

Tissue Regenix Group

Confirmation of Board appointments

RNS Number : 5173K
Tissue Regenix Group PLC
05 January 2021
 

Tissue Regenix Group plc

Confirmation of Board appointments

Leeds, 5 January 2021 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Group") the regenerative medical devices company, announces that, following the Group's announcement on 4 December 2020, Brian Phillips and Trevor Phillips have been appointed to the Board as independent Non-Executive Directors of Tissue Regenix.

Brian Phillips is now Chair of the Audit Committee and Trevor Phillips is Chair of the Remuneration Committee. 

 

For more Information:

 

Tissue Regenix Group plc

Caitlin Pearson   Head of Communications  

 

Tel: 0330 430 3052

 

 

Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

Ben Maddison / Alex Price

Tel:  0207 710 7600

 

 

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.

 

Regulatory disclosures

Trevor Michael Phillips, 59, has been a director or partner of the following companies or partnerships during the past five years:

Current directorships/partnerships

Directorships/partnerships within the last 5 years

Prostratex Limited

Vectura Group Investments Limited

NEPeSMO Limited

hVIVO Limited

 

hVIVO Services Limited

 

Open Orphan plc

 

Morvus Technology Limited

 

Prep Biopharm Limited

Imutex Limited

 

Quadrant Drug Delivery Limited

 

QDose Limited

 

Quadrant Technologies Limited

 

Quadrant Healthcare Limited

 

Quadrant Holdings Cambridge Limited

 

Quadrant Healthcare (UK) Limited

 

Quadrant Trustee Limited

 

Quadrant Bioresources Limited

 

Protosome Limited

 

Andaris Group Limited

 

Andaris (DDS) Limited

 

Microshot Limited

 

Innovata Biomed Limited

 

Innovata Limited

 

Vectura Group Services Limited

 

Trevor holds no shares in Tissue Regenix plc and there are no further disclosures required in accordance with AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

George Brian Phillips, 60, has been a director or partner of the following companies or partnerships during the past five years:

Current directorships/partnerships

Directorships/partnerships within the last 5 years

NAHL Group plc

Dig Space Limited

Muirfield Finance Limited

Tanygraig Limited

Muirfield Midco Limited

Preoday Limited

Muirfield Holdco Limited

 

Motocaddy Holdings Limited

 

Motocaddy Limited

 

Ethos Partners LLP

 

Imbiba Capital Limited

 

Imbiba (FP) LLP

 

Imbiba (GP) LLP

 

Imbiba Growth LLP


Purple Dragon (Holdings) Limited

 

Qikserve Limited

 

E&P Data Licensing Limited

 

The Jane Bubear Sport Foundation

 

 

Brian Phillips was a director of Valiant Sport Holdings Limited at the time it was placed into voluntary liquidation by members and creditors on 2 April 2013. The company was dissolved on 5 September 2014. There were no secured or preferential creditors. Unsecured creditors holding approximately £2.65m in aggregate received 0.7124p in pound.

Brian holds no shares in Tissue Regenix plc and there are no further disclosures required in accordance with AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFLFFTLEISIIL

a d v e r t i s e m e n t